President and Chief Medical Officer, Ophthalmology, Kriya Therapeutics
Theresa Heah is the President and Chief Medical Officer, Opthalmology, for Kriya Therapeutics. Previously, she was the Chief Medical Officer, EVP Operations for AsclepiX Therapeutics where she was responsible for the business strategy, Series A financing, R&D, clinical development, and regulatory strategy. Prior to joining AsclepiX Therapeutics, Dr. Heah served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), where she worked on developing gene therapies in ophthalmology and rare diseases. Theresa brings over two decades of Global Pharmaceutical Leadership experience, including in the core business area of ophthalmology drug development and commercialization in early-stage private-staged companies, public-staged and big pharmaceuticals. She has a diverse leadership perspective across Clinical, R&D, Medical Affairs, Marketing, and Business Development. Dr. Heah led global ophthalmologic innovation with multiple successful regulatory submissions in the U.S., Europe, and Japan. While at Bayer, she launched EYLEA successfully into a blockbuster drug. Dr. Heah received her medical degree from Guy’s Kings and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in business administration from the European School of Management & Technology (ESMT), Berlin.